TABLE OF CONTENTS
1 INTRODUCTION 75
1.1 OBJECTIVES OF THE STUDY 75
1.2 MARKET DEFINITION 75
1.3 OVERVIEW OF THE GLOBAL FECAL OCCULT BLOOD TESTS MARKET 75
1.4 CURRENCY AND PRICING 77
1.5 LIMITATIONS 77
1.6 MARKETS COVERED 77
2 MARKET SEGMENTATION 81
2.1 MARKETS COVERED 81
2.2 GEOGRAPHICAL SCOPE 82
2.3 YEARS CONSIDERED FOR THE STUDY 83
2.4 DBMR TRIPOD DATA VALIDATION MODEL 84
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 87
2.6 MULTIVARIATE MODELLING 88
2.7 PRODUCT TYPE SEGMENT LIFELINE CURVE 88
2.8 MARKET APPLICATION COVERAGE GRID 89
2.9 DBMR MARKET POSITION GRID 90
2.10 VENDOR SHARE ANALYSIS 91
2.11 SECONDARY SOURCES 92
2.12 ASSUMPTIONS 92
3 EXECUTIVE SUMMARY 93
4 PREMIUM INSIGHTS 95
4.1 PESTEL ANALYSIS 98
4.2 PORTER'S 5 FORCES 99
5 INDUSTRY INSIGHTS 100
6 REGULATORY FRAMEWORK 102
6.1 REGULATORY SCENARIO BY U.S. FDA 102
6.2 REGULATORY SCENARIO IN U.S. 102
6.3 REGULATORY SCENARIO IN EUROPE 103
6.4 REGULATORY SCENARIO IN CANADA 103
6.5 REGULATORY SCENARIO IN AUSTRALIA 103
7 MARKET OVERVIEW 104
7.1 DRIVERS 106
7.1.1 RISING CASES OF COLORECTAL CANCER GLOBALLY 106
7.1.2 DEVELOPMENT OF DIRECT-TO-CONSUMER LABORATORY TESTING 106
7.1.3 EASY AVAILABILITY OF FECAL OCCULT IMMUNOLOGICAL TEST DEVICES IN ONLINE STORES 107
7.1.4 INCREASING INCLINATION TOWARDS POINT-OF-CARE DIAGNOSTICS 107
7.2 RESTRAINTS 107
7.2.1 CHANGE IN CONSUMER PREFERENCE TOWARDS COST-EFFECTIVE ALTERNATIVES 107
7.2.2 LOW AWARENESS ABOUT FECAL OCCULT BLOOD TESTS IN UNDEVELOPED COUNTRIES 108
7.3 OPPORTUNITIES 108
7.3.1 INCREASE IN SCREENING PROCEDURES 108
7.3.2 RISING TECHNICAL ADVANCEMENTS 109
7.3.3 STRATEGIC INITIATIVES 109
7.4 CHALLENGES 110
7.4.1 LACK OF SKILLED PROFESSIONALS 110
7.4.2 LOW EFFICIENCY 110
8 GLOBAL FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE 111
8.1 OVERVIEW 112
8.2 LATERAL FLOW IMMUNO-FOB TEST KITS 115
8.3 IMMUNO-FOB AGGLUTINATION TEST KITS 115
8.4 IMMUNO-FOB ELISA TEST KITS 116
8.5 GUAIAC FOB STOOL TEST 117
8.5.1 KITS 118
8.5.1.1 GUAIAC SLIDES 118
8.5.1.1.1 25 PACKAGE 118
8.5.1.1.2 20 PACKAGE 118
8.5.1.1.3 OTHERS 118
8.5.1.2 ALPHA GUAIACONIC ACID (GUAIAC) IMPREGNATED PAPER 119
8.5.1.2.1 SENSITIVITY IS 50NG/ML 119
8.5.1.2.1.1 25 PACKAGE 119
8.5.1.2.1.2 20 PACKAGE 119
8.5.1.2.1.3 OTHERS 120
8.5.1.2.2 SENSITIVITY IS 75NG/ML 120
8.5.1.2.2.1 25 PACKAGE 120
8.5.1.2.2.2 20 PACKAGE 120
8.5.1.2.2.3 OTHERS 120
8.5.1.2.3 OTHERS 120
8.5.1.3 OTHERS 121
8.5.2 REAGENTS 121
8.5.2.1 HYDROGEN PEROXIDE 121
8.5.2.2 OTHERS 121
8.6 FLUSHABLE REAGENT PAD OR TISSUE 121
8.7 OTHERS 122
9 GLOBAL FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION 123
9.1 OVERVIEW 124
9.2 COLORECTAL CANCER SCREENING 127
9.2.1 LATERAL FLOW IMMUNO-FOB TEST KITS 128
9.2.2 IMMUNO-FOB AGGLUTINATION TEST KITS 128
9.2.3 IMMUNO-FOB ELISA TEST KITS 128
9.2.4 GUAIAC FOB STOOL TEST 128
9.2.5 FLUSHABLE REAGENT PAD OR TISSUE 128
9.2.6 OTHERS 128
9.3 CONCERN FOR GASTROINTESTINAL BLEEDING 128
9.3.1 LATERAL FLOW IMMUNO-FOB TEST KITS 129
9.3.2 IMMUNO-FOB AGGLUTINATION TEST KITS 129
9.3.3 IMMUNO-FOB ELISA TEST KITS 129
9.3.4 GUAIAC FOB STOOL TEST 130
9.3.5 FLUSHABLE REAGENT PAD OR TISSUE 130
9.3.6 OTHERS 130
9.4 POLYPS 130
9.4.1 LATERAL FLOW IMMUNO-FOB TEST KITS 131
9.4.2 IMMUNO-FOB AGGLUTINATION TEST KITS 131
9.4.3 IMMUNO-FOB ELISA TEST KITS 131
9.4.4 GUAIAC FOB STOOL TEST 131
9.4.5 FLUSHABLE REAGENT PAD OR TISSUE 131
9.4.6 OTHERS 131
9.5 DIVERTICULOSIS 132
9.5.1 LATERAL FLOW IMMUNO-FOB TEST KITS 133
9.5.2 IMMUNO-FOB AGGLUTINATION TEST KITS 133
9.5.3 IMMUNO-FOB ELISA TEST KITS 133
9.5.4 GUAIAC FOB STOOL TEST 133
9.5.5 FLUSHABLE REAGENT PAD OR TISSUE 133
9.5.6 OTHERS 133
9.6 ULCERS 133
9.6.1 LATERAL FLOW IMMUNO-FOB TEST KITS 134
9.6.2 IMMUNO-FOB AGGLUTINATION TEST KITS 134
9.6.3 IMMUNO-FOB ELISA TEST KITS 134
9.6.4 GUAIAC FOB STOOL TEST 135
9.6.5 FLUSHABLE REAGENT PAD OR TISSUE 135
9.6.6 OTHERS 135
9.7 HAEMORRHOIDS 135
9.7.1 LATERAL FLOW IMMUNO-FOB TEST KITS 136
9.7.2 IMMUNO-FOB AGGLUTINATION TEST KITS 136
9.7.3 IMMUNO-FOB ELISA TEST KITS 136
9.7.4 GUAIAC FOB STOOL TEST 136
9.7.5 FLUSHABLE REAGENT PAD OR TISSUE 136
9.7.6 OTHERS 136
9.8 COLITIS 137
9.8.1 LATERAL FLOW IMMUNO-FOB TEST KITS 138
9.8.2 IMMUNO-FOB AGGLUTINATION TEST KITS 138
9.8.3 IMMUNO-FOB ELISA TEST KITS 138
9.8.4 GUAIAC FOB STOOL TEST 138
9.8.5 FLUSHABLE REAGENT PAD OR TISSUE 138
9.8.6 OTHERS 138
9.9 ANEMIA 138
9.9.1 LATERAL FLOW IMMUNO-FOB TEST KITS 139
9.9.2 IMMUNO-FOB AGGLUTINATION TEST KITS 139
9.9.3 IMMUNO-FOB ELISA TEST KITS 139
9.9.4 GUAIAC FOB STOOL TEST 140
9.9.5 FLUSHABLE REAGENT PAD OR TISSUE 140
9.9.6 OTHERS 140
9.10 OTHERS 140
10 GLOBAL FECAL OCCULT BLOOD TESTS MARKET, BY END USER 141
10.1 OVERVIEW 142
10.2 DIAGNOSTIC LABORATORIES 145
10.3 HOSPITALS 145
10.4 SPECIALITY CLINICS 146
10.5 OTHERS 147
11 GLOBAL FECAL OCCULT BLOOD TESTS MARKET, BY DISTRIBUTION CHANNEL 148
11.1 OVERVIEW 149
11.2 DIRECT TENDER 152
11.3 RETAIL SALE 152
11.4 E-COMMERCE 153
11.5 OTHERS 154
12 GLOBAL FECAL OCCULT BLOOD TESTS MARKET, BY REGION 155
12.1 OVERVIEW 156
12.2 NORTH AMERICA 161
12.2.1 U.S. 174
12.2.2 CANADA 182
12.2.3 MEXICO 190
12.3 ASIA-PACIFIC 198
12.3.1 CHINA 211
12.3.2 JAPAN 219
12.3.3 INDIA 227
12.3.4 AUSTRALIA 235
12.3.5 SOUTH KOREA 243
12.3.6 THAILAND 252
12.3.7 SINGAPORE 260
12.3.8 INDONESIA 268
12.3.9 MALAYSIA 277
12.3.10 PHILIPPINES 286
12.3.11 REST OF ASIA-PACIFIC 295
12.4 EUROPE 296
12.4.1 GERMANY 311
12.4.2 FRANCE 321
12.4.3 U.K. 331
12.4.4 ITALY 341
12.4.5 SPAIN 351
12.4.6 RUSSIA 361
12.4.7 SWITZERLAND 371
12.4.8 NETHERLANDS 381
12.4.9 TURKEY 391
12.4.10 BELGIUM 401
12.4.11 REST OF EUROPE 411
12.5 SOUTH AMERICA 412
12.5.1 BRAZIL 427
12.5.2 ARGENTINA 437
12.5.3 REST OF SOUTH AMERICA 447
12.6 MIDDLE EAST AND AFRICA 448
12.6.1 SOUTH AFRICA 463
12.6.2 SAUDI ARABIA 473
12.6.3 U.A.E. 483
12.6.4 EGYPT 493
12.6.5 ISRAEL 503
12.6.6 REST OF MIDDLE EAST AND AFRICA 513
13 GLOBAL FECAL OCCULT BLOOD TESTS MARKET: COMPANY LANDSCAPE 514
13.1 COMPANY SHARE ANALYSIS: GLOBAL 514
13.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 515
13.3 COMPANY SHARE ANALYSIS: EUROPE 516
13.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 517
14 SWOT ANALYSIS 518
15 COMPANY PROFILE 519
15.1 QUIDEL CORPORATION 519
15.1.1 COMPANY SNAPSHOT 519
15.1.2 REVENUE ANALYSIS 519
15.1.3 COMPANY SHARE ANALYSIS 520
15.1.4 PRODUCT PORTFOLIO 520
15.1.5 RECENT DEVELOPMENT 520
15.2 WONDFO. 521
15.2.1 COMPANY SNAPSHOT 521
15.2.2 COMPANY SHARE ANALYSIS 521
15.2.3 PRODUCT PORTFOLIO 522
15.2.4 RECENT DEVELOPMENT 522
15.3 SIEMENS HEALTHCARE GMBH 523
15.3.1 COMPANY SNAPSHOT 523
15.3.2 REVENUE ANALYSIS 523
15.3.3 COMPANY SHARE ANALYSIS 524
15.3.4 RODUCT PORTFOLIO 524
15.3.5 RECENT DEVELOPMENT 524
15.4 EIKEN CHEMICAL CO., LTD. 525
15.4.1 COMPANY SNAPSHOT 525
15.4.2 REVENUE ANALYSIS 525
15.4.3 COMPANY SHARE ANALYSIS 526
15.4.4 PRODUCT PORTFOLIO 526
15.4.5 RECENT DEVELOPMENT 526
15.5 BIOHIT OYJ 527
15.5.1 COMPANY SNAPSHOT 527
15.5.2 REVENUE ANALYSIS 527
15.5.3 COMPANY SHARE ANALYSIS 528
15.5.4 PRODUCT PORTFOLIO 528
15.5.5 RECENT DEVELOPMENT 528
15.6 ACCUBIOTECH CO LTD 529
15.6.1 COMPANY SNAPSHOT 529
15.6.2 PRODUCT PORTFOLIO 529
15.6.3 RECENT DEVELOPMENT 529
15.7 ACCUQUIK TEST KITS 530
15.7.1 COMPANY SNAPSHOT 530
15.7.2 PRODUCT PORTFOLIO 530
15.7.3 RECENT DEVELOPMENT 530
15.8 AIDIAN 531
15.8.1 COMPANY PROFILE 531
15.8.2 PRODUCT PORTFOLIO 531
15.8.3 RECENT DEVELOPMENT 531
15.9 ALFA SCIENTIFIC DESIGNS, INC. 532
15.9.1 COMPANY SNAPSHOT 532
15.9.2 PRODUCT PORTFOLIO 532
15.9.3 RECENT DEVELOPMENT 532
15.10 APACOR LIMITED 533
15.10.1 COMPANY SNAPSHOT 533
15.10.2 PRODUCT PORTFOLIO 533
15.10.3 RECENT DEVELOPMENT 533
15.11 BIOPANDA REAGENTS LTD 534
15.11.1 COMPANY SNAPSHOT 534
15.11.2 PRODUCT PORTFOLIO 534
15.11.3 RECENT DEVELOPMENT 534
15.12 BODITECH MED INC. 535
15.12.1 COMPANY SNAPSHOT 535
15.12.2 PRODUCT PORTFOLIO 535
15.12.3 RECENT DEVELOPMENT 535

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.